Nestlé agreed to sell its mainstream Vitamins, Minerals and Supplements business alongside its Holistic Health portfolio to an undisclosed private equity firm for approximately $1 billion. The transaction marks the Swiss food conglomerate's formal exit from retail wellness categories it entered through acquisition over the past decade, including Garden of Life and other mass-market supplement brands.

The divestiture removes roughly 2% of Nestlé's North American revenue base. Management cited portfolio optimization and capital reallocation toward higher-margin nutrition categories as rationale. The VMS segment posted low-single-digit organic growth over the trailing three years, significantly below the company's mid-single-digit target for health science divisions. Completion is expected in late 2025, subject to regulatory clearance in the United States and Canada.

The sale reflects what allocators already suspected: consumer wellness is bifurcating. Premium brands with direct-to-consumer infrastructure and clinical differentiation command 30-40% gross margins. Mass-market shelf products in the vitamin aisle—where Nestlé competed—face 18-22% margins and perpetual promotional pressure from Amazon's private label and vertical integrators like Thorne and Ritual. Nestlé's decision to exit confirms that scale without pricing power is a liability in nutritional supplements. The buyer, likely a lower-middle-market PE firm with operational expertise in consumer turnarounds, is betting it can extract 200-300 basis points of EBITDA margin through SKU rationalization and retail renegotiation. That playbook worked for Bountiful Company before its 2021 sale to KKR at 14x EBITDA, but demand elasticity has tightened since.

For Nestlé, the $1 billion proceeds will likely fund M&A in medical nutrition or premiumization of its core coffee and pet care franchises, where it holds defendable margin structures. The company has telegraphed interest in GLP-1-adjacent nutrition products and clinical meal replacements, categories where reimbursement tailwinds could justify 25%+ EBITDA margins by 2027. Selling the VMS business now, before a potential consumer recession compresses multiples further, locks in a valuation near 8-9x trailing EBITDA—reasonable for a no-growth asset in a commoditizing category.

Watch for the buyer's identity within 30 days, as financing commitments typically leak during Hart-Scott-Rodino filings. If it's a sponsor with a track record in naturals retail—Swander Pace, Stride Consumer, or similar—the thesis is cost-out and wholesale exit. If it's a strategic aggregator, they're building a house brand to compete with Unilever's prestige nutrition portfolio. Either way, Nestlé's competitors in functional foods will read this as permission to divest their own underperforming wellness experiments.

The transaction also confirms that $1 billion is now the floor for credible consumer health carve-outs. Anything smaller lacks the infrastructure to justify standalone ownership. Anything larger attracts strategic buyers who can afford to wait.